James White
About James White
James White is the Executive Director of US Medical Oncology, Lung, Emerging Tumors, & Abraxane at Bristol Myers Squibb, with extensive experience in medical affairs and oncology.
Current Role at Bristol Myers Squibb
James White is the Executive Director of US Medical Oncology, specializing in Lung, Emerging Tumors, and Abraxane, at Bristol Myers Squibb. In this role, he leads the development and execution of medical strategies for lung cancer and emerging tumors. His work involves extensive engagement with thought leaders and data generation within the oncology field.
Previous Experience at TG Therapeutics and Epizyme
Prior to his current role, James White served as the Executive Director of Medical Affairs Operations at TG Therapeutics, Inc. from 2020 to 2022. Before that, he was Executive Director of Medical Science Liaisons at Epizyme from 2019 to 2020. His responsibilities included spearheading medical strategies and liaising with medical science teams in these organizations.
Extensive Tenure at Bristol Myers Squibb
James White has a diverse and extensive history with Bristol Myers Squibb, where he held multiple leadership roles prior to his current position. From 2017 to 2019, he served as the Biomarker & Diagnostics Lead in US Medical Oncology. Between 2015 and 2017, he was the Lead of Solid Tumor Field Medical, and from 2014 to 2015, he was the National Team Lead for Field Medical Health-Systems. Additionally, he was the Associate Director of Field Medical Health-Systems from 2013 to 2014.
Educational Background in Pharmacy and Biochemistry
James White holds a Doctor of Pharmacy (Pharm.D.) from Nova Southeastern University (1997-2001) and a Master of Science (M.S.) in Applied Pharmacoeconomics from the University of Florida (2012-2013). He also studied Biochemistry at Florida State University from 1995 to 1997. His educational background provides a robust foundation for his work in oncology and medical affairs.
Early Career and Experience
James White began his career as a Clinical Pharmacist in Pediatric Critical Care at Wolfson Children's Hospital, where he worked from 2002 to 2007. He later worked at Amgen as a Senior Regional Medical Liaison from 2007 to 2013. These early roles provided him with valuable experience in clinical settings and medical communication, shaping his subsequent career in medical affairs and oncology.